Novel immunotherapy delivery approach safe and beneficial for some melanoma patients with leptomeningeal disease
A novel approach to administer intrathecal (IT) immunotherapy (directly into the spinal fluid) and intravenous (IV) immunotherapy was safe and improved survival in a subset of patients with leptomeningeal disease (LMD) from metastatic melanoma, according to interim analyses of a Phase I/Ib trial led by researchers at Â鶹ӳ» MD Anderson Cancer Center.
The study, published today in Nature Medicine, represents...
MD Anderson Research Highlights for March 29, 2023
Â鶹ӳ» MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
Dual immunotherapy plus chemotherapy before surgery improves patient outcomes in operable lung cancer
In a Phase II trial led by researchers from Â鶹ӳ» MD Anderson Cancer Center, adding ipilimumab to a neoadjuvant, or pre-surgical...
MD Anderson Research Highlights for March 8, 2023
Â鶹ӳ» MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Recent developments include overlooked proteins from long noncoding RNAs that likely play a functional...
